OBJECTIVE: The present study aimed to assess the impact of low-level laser (LLL) on low salivary flow rate in patients undergoing radiochemotherapy (RT-CT) for head and neck cancer. BACKGROUND DATA: LLL has shown efficiency in preventing hyposalivation in patients under different pathological conditions, including those undergoing RT-CT. METHODS: During all RT-CT, 17 patients received laser therapy and 10 received clinical care only. An Indium-Gallium-Aluminum-Phosphorus diode laser was punctually used for intraoral (660 nm, 40 mW, 10 J/cm(2), illuminated area 0.04 cm(2), 10 sec) and extraoral irradiation (780 nm, 15 mW, 3.8 J/cm(2), illuminated area 0.04 cm(2), 10 sec), three times a week and on alternate days, for a total of 21 sessions. Unstimulated salivary flow rate was assessed before the first RT session (N0), at the 15th RT session (N15), at the last RT session (Nf), and at 30 (N30) and 90 days after the end of the oncologic treatment (N90). RESULTS: At N15, Nf, and N30, patients treated with LLL showed significantly higher averages of salivary flow rate when compared with patients receiving clinical care only. CONCLUSIONS:LLL seems to be an efficient tool for mitigation of salivary hypofunction in patients undergoing RT for head and neck cancer.
RCT Entities:
OBJECTIVE: The present study aimed to assess the impact of low-level laser (LLL) on low salivary flow rate in patients undergoing radiochemotherapy (RT-CT) for head and neck cancer. BACKGROUND DATA: LLL has shown efficiency in preventing hyposalivation in patients under different pathological conditions, including those undergoing RT-CT. METHODS: During all RT-CT, 17 patients received laser therapy and 10 received clinical care only. An Indium-Gallium-Aluminum-Phosphorus diode laser was punctually used for intraoral (660 nm, 40 mW, 10 J/cm(2), illuminated area 0.04 cm(2), 10 sec) and extraoral irradiation (780 nm, 15 mW, 3.8 J/cm(2), illuminated area 0.04 cm(2), 10 sec), three times a week and on alternate days, for a total of 21 sessions. Unstimulated salivary flow rate was assessed before the first RT session (N0), at the 15th RT session (N15), at the last RT session (Nf), and at 30 (N30) and 90 days after the end of the oncologic treatment (N90). RESULTS: At N15, Nf, and N30, patients treated with LLL showed significantly higher averages of salivary flow rate when compared with patients receiving clinical care only. CONCLUSIONS: LLL seems to be an efficient tool for mitigation of salivary hypofunction in patients undergoing RT for head and neck cancer.
Authors: Aljaž Golež; Igor Frangež; Ksenija Cankar; Helena Ban Frangež; Maja Ovsenik; Lidija Nemeth Journal: Lasers Med Sci Date: 2021-08-19 Impact factor: 3.161
Authors: Margherita Gobbo; Elisabetta Merigo; Praveen R Arany; René-Jean Bensadoun; Alan Roger Santos-Silva; Luiz Alcino Gueiros; Giulia Ottaviani Journal: Front Oral Health Date: 2022-07-07
Authors: Jolien Robijns; Raj G Nair; Joy Lodewijckx; Praveen Arany; Andrei Barasch; Jan M Bjordal; Paolo Bossi; Anne Chilles; Patricia M Corby; Joel B Epstein; Sharon Elad; Reza Fekrazad; Eduardo Rodrigues Fregnani; Marie-Thérèse Genot; Ana M C Ibarra; Michael R Hamblin; Vladimir Heiskanen; Ken Hu; Jean Klastersky; Rajesh Lalla; Sofia Latifian; Arun Maiya; Jeroen Mebis; Cesar A Migliorati; Dan M J Milstein; Barbara Murphy; Judith E Raber-Durlacher; Hendrik J Roseboom; Stephen Sonis; Nathaniel Treister; Yehuda Zadik; René-Jean Bensadoun Journal: Front Oncol Date: 2022-08-30 Impact factor: 5.738